Clinical Trial Update: A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet [Phase 3]

View source ↗

Summary

Phase 3 bridging study investigating nalfurafine hydrochloride orally disintegrating tablet for uremic pruritus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uremic Pruritus

Drugs mentioned

• Nalfurafine hydrochloride orally disintegrating tablet (nalfurafine hydrochloride)

Snippet

Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. | Conditions: Uremic Pruritus | Phase 3 | Status: UNKNOWN